ASCO15: Array BioPharma, Inc. Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting
BOULDER, Colo., May 28, 2015 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 June 2, 2015 in Chicago, Illinois. These three products are currently advancing in a total of 6 pivotal trials, with top-line results expected in 2015 from both the NEMO (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT (selumetinib with dacarbazine in uveal melanoma patients) Phase 3 trials.
Ron Squarer, Chief Executive Officer of Array, noted, "We are encouraged to see eight ASCO abstracts reporting clinical results from Array-invented BRAF, MEK and HER2 drugs, while we await readouts later this year from two pivotal trials, NEMO and SUMIT."
The following is a summary of the presentations that will be given at ASCO:
ORAL PRESENTATIONS
Title: | A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment (Abstract #9007) |
Presenter: | Ryan J. Sullivan, MD |
Date: | Saturday, May 30, 3:27 - 3:39 p.m. CDT (Oral Presentation) |
Title: | A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) (Abstract #10507) |
Presenter: | Ping Chi, MD, PhD |
Date: | Monday, June 1, 5:12 - 5:24 p.m. CDT (Oral Presentation) |
POSTER PRESENTATIONS
Title: | A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (Abstract #9051) |
Presenter: | Rachel N. Grisham, MD |
Date: | Saturday, May 30, 1:15 - 4:45 p.m. CDT |
Abstract #9051 will also be discussed at the Poster Discussion Session on Saturday, May 30, 4:45 - 6:00 p.m. | |
Title: | Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer (Abstract #2509) |
Presenter: | Geoffrey R. Oxnard, MD |
Date: | Saturday, May 30, 1:15 2:30 p.m. CDT |
Title: | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors (Abstract #2583) |
Presenter: | Wasiru Olugbenga Saka |
Date: | Saturday, May 30, 1:15 2:30 p.m. CDT |
Title: | SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer (Abstract #4119) |
Presenter: | Vincent M. Chung, MD |
Date: | Monday, June 1, 8 11:30 a.m. CDT |
Title: | A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197 (Abstract #8046) |
Presenter: | Garth Andrew Nicholas, MD |
Date: | Monday, June 1, 8 11:30 a.m. CDT |
Title: | ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets) (Abstract #612) |
Presenter: | Cristiano Ferrario, MD |
Date: | Saturday, May 30, 8 11:30 a.m. CDT |
Trials in Progress posters will also showcase the trial designs for the Phase 3 binimetinib trial in low-grade serous ovarian cancer (MILO), two filanesib Phase 2 trials in multiple myeloma (combination with carfilzomib, and single agent (AfFIRM), two ipatasertib (GDC-0068) Phase 2 trials in breast cancer (FAIRLANE and LOTUS) and the LOXO-101 Phase 1 trial in solid tumors.
All abstracts can be accessed through the ASCO website, http://abstract.asco.org/. After the presentations and posters are public, they will be available as PDFs on Array's website at www.arraybiopharma.com.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies are currently advancing. These programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: | Tricia Haugeto |
(303) 386-1193 | |
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentations-at-the-2015-asco-annual-meeting-300089644.html
SOURCE Array BioPharma Inc.
Help employers find you! Check out all the jobs and post your resume.